173 related articles for article (PubMed ID: 34763482)
41. Management of Self-Injurious Behavior, Aggression, and Psychogenic Non-Epileptic Seizures in Patients With Tuberous Sclerosis: A Case Report With a Review of Literature.
Ortiz JF; Ruxmohan S; Gomez J; Lalama HA; Taylor A; Smith DW
Cureus; 2020 Nov; 12(11):e11715. PubMed ID: 33391947
[TBL] [Abstract][Full Text] [Related]
42. Brain Symptoms of Tuberous Sclerosis Complex: Pathogenesis and Treatment.
Mizuguchi M; Ohsawa M; Kashii H; Sato A
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206526
[TBL] [Abstract][Full Text] [Related]
43. Sclerotic bone lesions as a potential imaging biomarker for the diagnosis of tuberous sclerosis complex.
Brakemeier S; Vogt L; Adams LC; Zukunft B; Diederichs G; Hamm B; Budde K; Eckardt KU; Makowski MR
Sci Rep; 2018 Jan; 8(1):953. PubMed ID: 29343816
[TBL] [Abstract][Full Text] [Related]
44. Combined Targeting of mTOR and Akt Using Rapamycin and MK-2206 in The Treatment of Tuberous Sclerosis Complex.
Ji S; Lin W; Wang L; Ni Z; Jin F; Zha X; Fei G
J Cancer; 2017; 8(4):555-562. PubMed ID: 28367235
[TBL] [Abstract][Full Text] [Related]
45. Tuberous sclerosis complex and DNA repair.
Habib SL
Adv Exp Med Biol; 2010; 685():84-94. PubMed ID: 20687497
[TBL] [Abstract][Full Text] [Related]
46. A mouse model of craniofacial bone lesion of tuberous sclerosis complex.
Fang F; Wei X; Hu M; Liu F
Musculoskelet Regen; 2015; 1(1):. PubMed ID: 26052552
[TBL] [Abstract][Full Text] [Related]
47. Juvenile xanthogranuloma as a new type of skin lesions in tuberous sclerosis complex.
Lu Q; Shi XY; Wang YY; Zhang MN; Wang WZ; Wang J; Wang QH; Chen HM; Zou LP
Orphanet J Rare Dis; 2020 Jun; 15(1):147. PubMed ID: 32532290
[TBL] [Abstract][Full Text] [Related]
48. A newborn with convulsions 12 days after birth was misdiagnosed as neonatal intracranial hemorrhage: Case report.
Che Y; Zhong J; Chen Y; Xie J; Wang R; Xu Y; Zha J; Zeng M; Chen H
Medicine (Baltimore); 2023 Dec; 102(52):e36675. PubMed ID: 38206725
[TBL] [Abstract][Full Text] [Related]
49. Tuberous sclerosis complex: a case report and literature review.
Li Y; Si Z; Zhao W; Xie C; Zhang X; Liu J; Liu J; Xia Z
Ital J Pediatr; 2023 Sep; 49(1):116. PubMed ID: 37679848
[TBL] [Abstract][Full Text] [Related]
50. Evidence for population variation in TSC1 and TSC2 gene expression.
Jentarra GM; Rice SG; Olfers S; Saffen D; Narayanan V
BMC Med Genet; 2011 Feb; 12():29. PubMed ID: 21345208
[TBL] [Abstract][Full Text] [Related]
51. Tuberous Sclerosis Complex: State-of-the-Art Review with a Focus on Pulmonary Involvement.
von Ranke FM; Zanetti G; e Silva JL; Araujo Neto CA; Godoy MC; Souza CA; Mançano AD; Souza AS; Escuissato DL; Hochhegger B; Marchiori E
Lung; 2015 Oct; 193(5):619-27. PubMed ID: 26104489
[TBL] [Abstract][Full Text] [Related]
52. Analysis of 65 tuberous sclerosis complex (TSC) patients by TSC2 DGGE, TSC1/TSC2 MLPA, and TSC1 long-range PCR sequencing, and report of 28 novel mutations.
Rendtorff ND; Bjerregaard B; Frödin M; Kjaergaard S; Hove H; Skovby F; Brøndum-Nielsen K; Schwartz M;
Hum Mutat; 2005 Oct; 26(4):374-83. PubMed ID: 16114042
[TBL] [Abstract][Full Text] [Related]
53. Loss of heterozygosity in the tuberous sclerosis (TSC2) region of chromosome band 16p13 occurs in sporadic as well as TSC-associated renal angiomyolipomas.
Henske EP; Neumann HP; Scheithauer BW; Herbst EW; Short MP; Kwiatkowski DJ
Genes Chromosomes Cancer; 1995 Aug; 13(4):295-8. PubMed ID: 7547639
[TBL] [Abstract][Full Text] [Related]
54. Tuberous sclerosis complex: From molecular biology to novel therapeutic approaches.
Switon K; Kotulska K; Janusz-Kaminska A; Zmorzynska J; Jaworski J
IUBMB Life; 2016 Dec; 68(12):955-962. PubMed ID: 27797139
[TBL] [Abstract][Full Text] [Related]
55. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
[TBL] [Abstract][Full Text] [Related]
56. [Analysis of genotypes, EEG and phenotypes of tuberous sclerosis complex patients].
He J; Zhou WJ; Shi J; Lin JL; Zhang BQ; Sun ZH
Zhonghua Yi Xue Za Zhi; 2020 Jan; 100(2):136-140. PubMed ID: 31937054
[No Abstract] [Full Text] [Related]
57. Autopsy case of right ventricular rhabdomyoma in tuberous sclerosis complex.
Kondo T; Niida Y; Mizuguchi M; Nagasaki Y; Ueno Y; Nishimura A
Leg Med (Tokyo); 2019 Feb; 36():37-40. PubMed ID: 30336374
[TBL] [Abstract][Full Text] [Related]
58. Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.
Lee N; Woodrum CL; Nobil AM; Rauktys AE; Messina MP; Dabora SL
BMC Pharmacol; 2009 Apr; 9():8. PubMed ID: 19368729
[TBL] [Abstract][Full Text] [Related]
59. Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779.
Messina MP; Rauktys A; Lee L; Dabora SL
BMC Pharmacol; 2007 Nov; 7():14. PubMed ID: 17986349
[TBL] [Abstract][Full Text] [Related]
60. Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition.
Budde K; Gaedeke J
Am J Kidney Dis; 2012 Feb; 59(2):276-83. PubMed ID: 22130643
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
